Market Cap 210.04M
Revenue (ttm) 0.00
Net Income (ttm) -19.00M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 33,400
Avg Vol 92,658
Day's Range N/A - N/A
Shares Out 25.62M
Stochastic %K 49%
Beta -0.30
Analysts Strong Sell
Price Target $18.00

Company Profile

Nuvectis Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious conditions of unmet medical need in oncology. Its lead product candidate is NXP800, a novel small molecule that is in Phase 1b clinical trial for the treatment of patients with platinum-resistant ARID1a-mutated ovarian carcinoma. The company is also developing NXP900, a small molecule drug candidate, which is in Phase 1a clinical trial that inhibits th...

Industry: Biotechnology
Sector: Healthcare
Phone: 201 614 3150
Address:
1 Bridge Plaza, Suite 275, Fort Lee, United States
safari_jne
safari_jne Jan. 14 at 12:08 PM
$NVCT just came across NXP900. Very interesting player in the Hippo-pathway space and looks like it'd especially have potential in combination therapy, though in-vitro single-agent also appears pretty potent. I like that their approach is very unique compared to other molecules. Now that Novartis and other early players are dropping out of this race, I'll definitely keep an eye out for this one.
0 · Reply
BioTrade2
BioTrade2 Jan. 12 at 10:53 PM
$NVCT anyone spot the management team at JPM? Are they meeting with any investors?
1 · Reply
WallStWireAds
WallStWireAds Jan. 8 at 5:35 PM
$NVCT https://www.bioreview.com/why-one-of-lung-cancers-best-drugs-eventually-stops-working-and-how-nuvectis-pharma-is-trying-to-fix-that/
0 · Reply
Elgallo353
Elgallo353 Jan. 8 at 4:31 PM
$NVCT something is brewing , anybody knowledge of any insider buyong or major funds buying ?
1 · Reply
BillionerOfKing
BillionerOfKing Jan. 6 at 12:43 PM
$NVCT Current Stock Price: $8.52 Contracts to trade: $10 NVCT Jan 16 2026 Call Entry: $0.23 Exit: $0.44 ROI: 97% Hold ~24 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
biospeculator
biospeculator Jan. 5 at 11:59 AM
$NVCT News out on Friday clinicaltrials.gov. Dr Zofia Piotrowska named Principal investigator for the trial. This will attract the attention of institutional investors imo. GLTA
2 · Reply
biospeculator
biospeculator Jan. 4 at 2:14 PM
$NVCT Technical analysis update. A continued close above $8.5 for two days gives us an intermediate target of $11 which is the neckline of an inverse head and shoulders pattern. If this occurs a close above $12 will then give us our $20 target for this move. However, at $20 the market cap would still be a measly 500M. This market cap imo is extremely undervalued for the previous lack of institutional buying. That is now changing. GLTA
0 · Reply
biospeculator
biospeculator Jan. 2 at 9:15 PM
$NVCT A close for 2 days or more above $8.50 gives us a technical target of $18. My guess is that institutions are now finally buying with current positions as of last reporting date per NASDAQ at below 15%. GLTA
0 · Reply
Elgallo353
Elgallo353 Jan. 2 at 4:18 PM
$NVCT que pasa?
1 · Reply
UNLV
UNLV Dec. 24 at 2:00 AM
$NVCT big pharma isn’t sitting still yet I’m always seeing huge valuation metrics around NXP900. New 1L drugs with better efficacy complicate the NVCT combo therapy story around NSCLC resistance https://www.ajmc.com/view/weighing-osimertinib-vs-amivantamab-lazertinib-in-frontline-egfr-nsclc-danny-nguyen-md
1 · Reply
Latest News on NVCT
Nuvectis Pharma to Participate in the 37th Annual Roth Conference

Mar 14, 2025, 8:00 AM EDT - 10 months ago

Nuvectis Pharma to Participate in the 37th Annual Roth Conference


Nuvectis Pharma to Present at the 36th Annual Roth Conference

Mar 15, 2024, 8:00 AM EDT - 1 year ago

Nuvectis Pharma to Present at the 36th Annual Roth Conference


Nuvectis: Early Stage Company That's Low On Cash

Sep 6, 2023, 8:03 AM EDT - 2 years ago

Nuvectis: Early Stage Company That's Low On Cash


Nuvectis Pharma Announces FDA Clearance of NXP900 IND

May 15, 2023, 8:00 AM EDT - 2 years ago

Nuvectis Pharma Announces FDA Clearance of NXP900 IND


safari_jne
safari_jne Jan. 14 at 12:08 PM
$NVCT just came across NXP900. Very interesting player in the Hippo-pathway space and looks like it'd especially have potential in combination therapy, though in-vitro single-agent also appears pretty potent. I like that their approach is very unique compared to other molecules. Now that Novartis and other early players are dropping out of this race, I'll definitely keep an eye out for this one.
0 · Reply
BioTrade2
BioTrade2 Jan. 12 at 10:53 PM
$NVCT anyone spot the management team at JPM? Are they meeting with any investors?
1 · Reply
WallStWireAds
WallStWireAds Jan. 8 at 5:35 PM
$NVCT https://www.bioreview.com/why-one-of-lung-cancers-best-drugs-eventually-stops-working-and-how-nuvectis-pharma-is-trying-to-fix-that/
0 · Reply
Elgallo353
Elgallo353 Jan. 8 at 4:31 PM
$NVCT something is brewing , anybody knowledge of any insider buyong or major funds buying ?
1 · Reply
BillionerOfKing
BillionerOfKing Jan. 6 at 12:43 PM
$NVCT Current Stock Price: $8.52 Contracts to trade: $10 NVCT Jan 16 2026 Call Entry: $0.23 Exit: $0.44 ROI: 97% Hold ~24 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
biospeculator
biospeculator Jan. 5 at 11:59 AM
$NVCT News out on Friday clinicaltrials.gov. Dr Zofia Piotrowska named Principal investigator for the trial. This will attract the attention of institutional investors imo. GLTA
2 · Reply
biospeculator
biospeculator Jan. 4 at 2:14 PM
$NVCT Technical analysis update. A continued close above $8.5 for two days gives us an intermediate target of $11 which is the neckline of an inverse head and shoulders pattern. If this occurs a close above $12 will then give us our $20 target for this move. However, at $20 the market cap would still be a measly 500M. This market cap imo is extremely undervalued for the previous lack of institutional buying. That is now changing. GLTA
0 · Reply
biospeculator
biospeculator Jan. 2 at 9:15 PM
$NVCT A close for 2 days or more above $8.50 gives us a technical target of $18. My guess is that institutions are now finally buying with current positions as of last reporting date per NASDAQ at below 15%. GLTA
0 · Reply
Elgallo353
Elgallo353 Jan. 2 at 4:18 PM
$NVCT que pasa?
1 · Reply
UNLV
UNLV Dec. 24 at 2:00 AM
$NVCT big pharma isn’t sitting still yet I’m always seeing huge valuation metrics around NXP900. New 1L drugs with better efficacy complicate the NVCT combo therapy story around NSCLC resistance https://www.ajmc.com/view/weighing-osimertinib-vs-amivantamab-lazertinib-in-frontline-egfr-nsclc-danny-nguyen-md
1 · Reply
UNLV
UNLV Dec. 23 at 6:47 PM
$NVCT article touches upon my major query RESISTANCE. Stock currently 200M mc and the bigger the role NXP900 around resistance the bigger the ultimate valuation. Stay tuned currently there’s talk SRC is a minor resistance pathway I’m just letting the insider buying the article talks about play out
0 · Reply
UNLV
UNLV Dec. 23 at 3:11 PM
$NVCT let’s get through 1b on a high note with interest from large pharma before entertaining 1B valuations. BIG OPPORTUNITY imo but in the real world stock dilution huge without partnership and how big a role does SRC have on resistance
0 · Reply
WallStWireAds
WallStWireAds Dec. 23 at 1:54 PM
$NVCT https://thefinanceherald.com/big-pharmas-6-billion-drug-has-a-fatal-flaw-this-under-the-radar-biotech-may-have-the-fix-nasdaq-nvct/
0 · Reply
biospeculator
biospeculator Dec. 23 at 1:45 PM
$NVCT Fair value imo is 1B market cap or approx. $35 pps. Target is $5B-$15B with outstanding phase III results in the future. A buyout upon completion of a phase II trial with outstanding results is also possible. 2026 should be an outstanding year for NVCT. GLTA
2 · Reply
buyandsold
buyandsold Dec. 22 at 10:33 PM
$NVCT 2026 is the banner year.
0 · Reply
SuperGreenToday
SuperGreenToday Dec. 22 at 5:59 PM
$NVCT Share Price: $8.15 Contract Selected: Jul 17, 2026 $7.5 Calls Buy Zone: $1.44 – $1.78 Target Zone: $2.71 – $3.32 Potential Upside: 77% ROI Time to Expiration: 206 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
UNLV
UNLV Dec. 19 at 3:16 PM
$GOSS $NVCT $SGMO post I saw today by @boomupwego sounded panicky around $GOSS mass selling with further slide. Again NVCT has huge “INSIDER BUYING” game over
1 · Reply
WallStWireAds
WallStWireAds Dec. 17 at 10:14 PM
$NVCT https://www.benzinga.com/content/49462546/nuvectis-pharmas-new-phase-1b-trial-targets-a-major-lung-cancer-bottleneck-nasdaq-nvct
1 · Reply
UNLV
UNLV Dec. 17 at 8:44 PM
$NVCT up from recent 5.80 initiation of combo therapy started and phase 1b brings together a large cohort of indications. Huge levels of INSIDER BUYING is how you pick small caps with supreme confidence and never, never forget this
0 · Reply
WallStWireAds
WallStWireAds Dec. 17 at 12:02 PM
$NVCT https://caplynx.io/ERhybbg
0 · Reply
WildChase1
WildChase1 Dec. 15 at 11:00 PM
0 · Reply
Max_Prophet26
Max_Prophet26 Dec. 13 at 1:28 AM
$GOSS $NVCT $SGMO No thanks. I’ll stick with GOSS for now….
1 · Reply